Frontline Workers in DRC Vaccinated with Ervebo Amid Ebola Surge
Health workers in Beni, DRC, received the Ervebo vaccine as the country faces a severe Ebola outbreak, with over 9,000 confirmed cases.
Over 9,000 confirmed Ebola cases reported in DRC, with 4,381 deaths.
Ervebo vaccine administered under compassionate-use program amid ongoing outbreak.
WHO warns the outbreak could surpass the deadly 2014-2016 West Africa epidemic.
On Friday, health care professionals in Beni, Democratic Republic of Congo, were vaccinated with the Ervebo vaccine, which has shown efficacy against the Zaire strain of Ebola in previous outbreaks. This vaccination effort comes as the country grapples with a significant Ebola outbreak, currently the deadliest in its history, with the Health Ministry reporting over 9,000 confirmed cases and 4,381 fatalities.
The Ervebo vaccine is being utilized under a compassionate-use protocol, allowing its application in serious health crises despite lacking specific approval for the current situation. Dr. Mohamed Janabi, the regional director for Africa at the World Health Organization, emphasized the importance of the vaccine, stating that it may offer some protection against the Bundibugyo strain, although further studies are needed to confirm its effectiveness against this variant.
Stella Nyota, a nurse who received the vaccine, expressed relief, stating that it provides reassurance while working closely with patients. The WHO has reported that approximately 2,400 individuals have survived Ebola during this ongoing outbreak, highlighting the critical need for effective medical interventions.
The outbreak, primarily affecting Ituri province, is exacerbated by challenging conditions, including insecurity, population displacement, and a strike among health workers. The WHO has characterized the situation as out of control, warning that it is on track to exceed the fatalities of the 2014-2016 West Africa Ebola outbreak, which claimed over 11,000 lives.
In response to the crisis, the WHO announced in August that 70,000 doses of the Ervebo vaccine had been approved for use in Congo. Of these, 50,000 doses are allocated for frontline health workers, while 20,000 doses are designated for a clinical trial to assess the vaccine's efficacy against the Bundibugyo virus, which is currently responsible for the outbreak and lacks an approved vaccine or treatment.
